{"name":"Kang Stem Biotech Co., Ltd.","slug":"kang-stem-biotech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"FURESTEM-AD Inj.","genericName":"FURESTEM-AD Inj.","slug":"furestem-ad-inj","indication":"Atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"FURESTEM-AD Inj.","genericName":"FURESTEM-AD Inj.","slug":"furestem-ad-inj","phase":"phase_3","mechanism":"FURESTEM-AD is an allogeneic adipose tissue-derived mesenchymal stem cell product that modulates immune responses and promotes tissue repair in atopic dermatitis.","indications":["Atopic dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWFhFT2RROUMwS0doQ2tWSmJjN1Rjb2ZHTG1wSkpfTUx5SlJqeDBfRjE4TmdkVEJfM1pYUmo0c2hkbmlkVWRMUkQ3M3ZjblBBb0RpN0hDOXdJaUxOUG5SLWdvbGtsVkJhUjFHRmo0SHhFeFItUU5TclFOVHJ3N2lyUm5oMnF1a25qX0QzdzhmMFNxMVY3b1hlbUJlTFlzUExCbzZENnllUHROTUFyY2RZWlRB?oc=5","date":"2025-08-25","type":"pipeline","source":"Fierce Biotech","summary":"Cell therapy biotech Appia shuts down as funding runs dry - Fierce Biotech","headline":"Cell therapy biotech Appia shuts down as funding runs dry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVEdWY19ONURpSzFuSU80eUZQWWYyMjViZ2VGZDgzUGVtSUFqRnJHaFdJT1NyQ1E1Q2Q3ZTJ1ejB5YS1FSFFkMDJaR0pBZXpWSFpkdkphOHVpUzE4MTRMMkRLWXk4LXdKZE1va0JYejRBaWFlWUNsMmNvSXYycXdlaE1sUWRlZVljV3ZhcHBJeWQ5QUNlVVow0gGcAUFVX3lxTE1IbWxwWDJSTU96UHFyU3NXYmtza3hTUVJBanVnZV83Vk9mWHBOU2Z2UnZDY1B6S0p1b1l2WnFOV3RUcXlteTdqZmFCMGVwWEgydTFrN2lIWnYxdVNtQ1B6dHVNalVhQTFrbjVEa1FJZ1ZZNWx2dTQ0QS1oU2JmcUcxQzNnbjJzYk5ac2RwNkRENjVMVVItZEl6OHJ2cg?oc=5","date":"2015-09-11","type":"trial","source":"BioInformant","summary":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More - BioInformant","headline":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZUdiMUI2RERBcXVHOGg4c1g3Y0Z2QzhwcTF4NTBaazBsOEE0MXdPTl93NEctQkE4Q1QzQTV4RFBrU0RhVXFmeUZnV3ZUT3l3Nmc3MzFraVRDT2Fvdkp3M3cxXy0yUmFhd3NnWm5uZ2pSZ3BqampMcGh0czl2ZWNFemJJYkZTcXdpd01PcS10NW1GSTBiYm5wMWhxc2xLTUlTSGkwT09lQVB4aFJvT0JfdVgzdXRnWnd6bnR3?oc=5","date":"2013-05-13","type":"regulatory","source":"Asian Scientist Magazine","summary":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma - Asian Scientist Magazine","headline":"Sagent Pharma To Acquire Remaining Interest In Chengdu Kanghong Pharma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}